文献速递其他结缔组织病

抗磷脂综合征中血小板Pannexin-1通道的促血栓激活

Prothrombotic Activation of Platelet Pannexin-1 Channels in Antiphospholipid Syndrome.
PubMed 文献 · Arthritis Rheumatol · 2026-01-29

研究评估血小板PANX1通道在抗磷脂综合征(APS)病理生理中的作用,发现APS患者血小板基础ATP释放显著高于对照,且PANX抑制剂可逆转;APS IgG通过PANX1磷酸化增强ATP释放和血小板活化,提示阻断PANX1可能恢复血小板稳态而不影响止血。

要点

  • APS患者血小板基础ATP释放显著高于健康对照,PANX抑制剂可使其正常化。
  • APS IgG通过增强PANX1酪氨酸-308磷酸化促进ATP释放和血小板活化。
  • 阻断PANX1或P2X1受体可减少APS IgG诱导的血小板聚集和P-选择素表达。

核心结论

  • PANX1通道可能是APS中血小板活化的重要介质,阻断PANX1可能恢复血小板稳态并限制血栓形成而不损害止血。

研究设计与样本

  • 研究纳入持续抗磷脂抗体阳性患者36例、系统性红斑狼疮患者10例和健康对照16例,测量血小板细胞外ATP释放,部分实验用PANX抑制剂卡苯氧酮预处理纯化血小板,并评估血小板信号、P-选择素暴露和聚集。

主要发现

  • APS血小板基础ATP释放显著高于对照(P < 0.0001),卡苯氧酮存在下正常化(P = 0.03)。
  • 卡苯氧酮降低凝血酶诱导的血小板ATP释放和表面P-选择素表达(P = 0.002和P = 0.02),也降低convulxin诱导的相应指标(P = 0.0001和P = 0.0012)。
  • 对照血小板经APS患者IgG刺激后PANX1酪氨酸-308磷酸化增强(P = 0.03),伴ATP释放增强(P = 0.0004)。
  • APS IgG增强ADP诱导的聚集(P = 0.0011),卡苯氧酮可减少该聚集(P = 0.0007)。
  • 钙螯合剂BAPTA-AM减少APS IgG介导的ATP释放(P = 0.03)、P-选择素表达(P = 0.0005)和聚集(P = 0.0007);P2X1受体脱敏剂α,β-MeATP减少APS IgG诱导的P-选择素表达(P = 0.0002)和聚集(P = 0.01)。

临床怎么用

  • PANX1通道可能成为APS抗血栓治疗的新靶点,阻断PANX1或下游P2X1受体或可抑制血小板活化而不影响止血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: ATP is released from platelets through both degranulation and pannexin-1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium-dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired thromboinflammatory disorder characterized by platelet-activating antiphospholipid antibodies. METHODS: Extracellular ATP release was measured in platelets isolated from patients with persistently positive antiphospholipid antibodies (n = 36), patients with systemic lupus erythematosus (n = 10), and healthy controls (n = 16). In some assays, purified platelets were pretreated with the PANX inhibitor carbenoxolone. Platelet signaling, P-selectin exposure, and aggregation were assessed. RESULTS: Basal ATP release was significantly higher in APS platelets than in controls (P < 0.0001) and normalized in the presence of carbenoxolone (P = 0.03). Carbenoxolone also reduced platelet ATP release and surface P-selectin expression induced by thrombin (P = 0.002 and P = 0.02, respectively) and convulxin (P = 0.0001 and P = 0.0012). Control platelets stimulated with IgG from patients with APS demonstrated enhanced phosphorylation of PANX1 at tyrosine-308 (P = 0.03), which was accompanied by enhanced ATP release (P = 0.0004). APS IgG boosted ADP-induced aggregation (P = 0.0011), which was reduced by carbenoxolone (P = 0.0007). The calcium chelator BAPTA-AM decreased APS IgG-mediated ATP release (P = 0.03), P-selectin expression (P = 0.0005), and aggregation (P = 0.0007). Desensitizing P2X1 receptors with α,β-MeATP decreased APS IgG-induced P-selectin expression (P = 0.0002) and aggregation (P = 0.01). CONCLUSION: PANX1 channels appear to be important mediators of platelet activation in APS. Agents that block PANX1 may restore platelet homeostasis and limit thrombosis without impairing hemostasis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. de Moraes Mazetto Fonseca B, NaveenKumar SK, Yalavarthi S, et al. Prothrombotic Activation of Platelet Pannexin-1 Channels in Antiphospholipid Syndrome. Arthritis Rheumatol. 2026. PMID: 41327823. doi:10.1002/art.70001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。